Ultragenyx Corp (RARE) Long-Term Debt to Capital Ratio

This daily price chart for Ultragenyx Pharmaceutical (RARE) illustrates the price action of a company developing innovative DNA-based treatments. Its business relies on patent protection for unique therapies, which guarantees perpetual demand and transforms its products into reliable cash cows. The current metric stands at 0.00. Stable margin growth is driven by the commercialization of drugs regardless of economic conditions, although colossal R&D expenditures and insurance complexities remain key threats.

This ratio measures the proportion of long-term liabilities within the equity structure, determining the degree of financial leverage and the risk of dependence on borrowing costs. Analyzing the history of long-term debt-to-equity with a current value of 0.00 allows for an assessment of how effectively Ultragenyx Pharmaceutical (RARE) finances its R&D without creating a critical burden when outsourcing drug production.